Yes, for-profit institutions institutions are eligible to apply.
 

Yes.
  

You do not have to be a U.S. citizen to apply, but applicants must apply from a domestic, U.S.-based institution. Foreign institutions are not eligible. However, foreign components as defined in the NIH Grants Policy Statement are allowed.
 

Yes, intramural investigators are eligible to apply to RFA-RM-24-009

Yes. These awards are considered R01-equivalents and will strip away an investigator’s ESI status. Learn more about ESI status at https://grants.nih.gov/grants/esi-status.pdf.
 

Yes, as long as the companies are a domestic, U.S.-based institution that is eligible for federal funding.
 

There is no requirement for MPIs, but it is allowed.
 

We are accepting multi-PI applications and there is no restriction on whether a PI from a foreign institution can lead or be involved in a core. As with all foreign components, an application must provide a good rationale and justification for having a core lead from a foreign institution, such as specific expertise or resources that can’t be obtained in the U.S.

• RFA-RM-24-009 – February 27, 2025
   

No, Letters of Intent are recommended but not required. Letters of Intent help NIH staff gauge the number of likely applications and consider potential review needs.
 

Applicants are asked to provide their name(s), names of other key personnel, name of the participating institution, and a descriptive title of the project. See section IV of the funding opportunity for more information.
 

No. The Letter of Intent is used to help NIH staff plan the review.
 

Yes. Applicants may submit more than one application, provided that each application is scientifically distinct as required by NIH policy.
 

The Human Virome Program funding opportunities use the cooperative agreement funding mechanism. A cooperative agreement supports discrete, specified, circumscribed projects to be performed by investigators in an area representing their specific interest and competencies, and is used when substantial NIH programmatic involvement is anticipated.
 

The Human Virome Program currently has no funding opportunities for R01s.
  

NIH intramural investigators are welcome to as PIs and/or to collaborate with extramural investigators.

Budget request for intramural investigators cannot include any salary and related fringe benefits for career, career conditional or other Federal employees (civilian or uniformed service) with permanent appointments under existing position ceilings or any costs related to administrative or facilities support (equivalent to Facilities and Administrative or F&A costs). Costs may include salary for staff to be specifically hired under a temporary appointment for the project, consultant costs, equipment, supplies, travel, and other items typically listed under Other Expenses. Applicants should indicate the number of person-months devoted to the project, even if no funds are requested for salary and fringe benefits. Should an extramural application include the collaboration with an intramural scientist, no funds for the support of the intramural scientist may be requested in the application. Only costs for the research are allowed as described above in the NIH Intramural Source Book.
  

Yes, they are considered as part of the human virome.
 

It would depend on what is meant by epigenetic modification and annotation. Please contact an HVP program official to discuss further.
 

The LOI is not binding. NIH uses LOIs in planning and coordinating the review process.
 

We understand that we currently do not know who the members of consortium will be, but it is expected that all the projects will work synergistically. Interconnectivity will be better established once the awards are made, and the steering committee is formed.
 

Preliminary data are encouraged.
 

The working groups will be formed on an on-need basis and based on the types of projects that will be awarded. We will have a better idea when the awards are made.
 

There is not a requirement on the # of samples for U01s.

Collaborative pilot projects will be proposed during the third project year for cross-validation of the developed tools, methods and technologies in the final project year. Collaborative pilot projects will be proposed by investigators and approved by NIH.
 

Applicants must budget funds in their final year for cross validation of their work products (e.g., shipping unique reagents, labor costs for reproducing methods) as part of the HPV consortium's Collaborative Pilot Projects. The amount of set aside was not pre-determined for -018 b/c this is for cross-validation and may range depending on the project.

Human Virome Program awards will be made in late summer/early fall 2024.
 

The first phase of the Human Virome Program is expected to run from FY2024 to FY2028.

Each RFA will have a special emphasis panel (SEP) and the composition of those panels will be made up depending on what type of applications come under each RFA to bring in the appropriate expertise. There are review criteria listed for each NOFO and the panel will reflect the expertise needed for the applications submitted for each NOFO.

There are no specific funding opportunities for postdocs in this program. However, postdocs may receive funding through grants to HVP PIs. If you are looking for general NIH funding for postdocs, look at career (K) awards. For Common Fund, depending on your situation, the High-Risk, High-Reward Research program may have some opportunities for you. Check out the New Innovator Award (requires independent research position) or Early Independence Award (requires recent graduation).
 

We can't speak of future funding opportunities for the program, but you are welcome to go to our website and sign up for the HVP listserv. You will be emailed when/if future funding opportunities are released.

A list of program officers is available at https://commonfund.nih.gov/humanvirome/fundingopportunities.